BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

PR Newswire

NEW YORK, Nov. 16, 2026

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

BrainStorm Logo

"ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase, and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community."

Recent Highlights

Clinical, Scientific, and Regulatory Progress

Corporate and Leadership

Industry and Investor Engagement

Financial Results for the Third Quarter Ended September 30, 2026

 

U.S. dollars in thousands

(Except share and per share amounts)










September 30, 


December 31, 



2026


2025



Unaudited


Audited



U.S. $ in thousands

ASSETS














Current Assets:







Cash and cash equivalents


$

163


$

29

Other accounts receivable



189



86

Prepaid expenses and other current assets



101



192

Total current assets


$

453


$

307








Long-Term Assets:







Prepaid expenses and other long-term assets


$

26


$

25

Restricted Cash



185



247

Right of use asset



53



208

Property and equipment, net



123



235

Total Long-Term Assets


$

387


$

715








Total assets


$

840


$

1,022








LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)














Current Liabilities:







Accounts payable


$

7,473


$

7,067

Accrued expenses



464



396

Short-term loans



1,875



967

Operating lease liability



56



208

Employees related liability



3,304



2,369

Total current liabilities


$

13,172


$

11,007















Total liabilities


$

13,172


$

11,007








Stockholders' Deficit:







Stock capital:



16



16

Common stock $0.00005 par value; 250,000,000 shares
authorized at September 30, 2026 and December 31,
2025; 14,259,377 and 11,034,775 shares issued and
outstanding at September 30, 2026 and December 31,
2025, respectively







Additional paid-in-capital



232,426



227,058

Treasury stock



(116)



(116)

Accumulated deficit



(244,658)



(236,943)

Total stockholders' deficit


$

(12,332)


$

(9,985)








Total liabilities and stockholders' deficit


$

840


$

1,022

 

The accompanying notes are an integral part of the consolidated financial statements.

 

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)


U.S. dollars in thousands

(Except share and per share amounts)
















Nine months ended


Three months ended



September 30, 


September 30, 



2026


2025


2026


2025



Unaudited


Unaudited

Operating expenses:


























Research and development, net


$

2,248


$

3,323


$

523


$

899

General and administrative



5,026



4,386



1,092



1,148














Operating loss



(7,274)



(7,709)



(1,615)



(2,047)














Financial income (expense), net



(441)



(343)



(118)



(59)














Gain (loss) on change in
fair value of Warrants
liability



-



179



-



-














Net loss


$

(7,715)


$

(7,873)


$

(1,733)


$

(2,106)














Basic and diluted net loss
per share from continuing
operations


$

(0.68)


$

(0.91)


$

(0.14)


$

(0.19)














Weighted average number
of shares outstanding used
in computing basic and
diluted net loss per share



11,354,405



8,673,908



11,983,241



11,008,047

 

About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect," a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will", "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at

http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investors:

Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com

Media:

Uri Yablonka, Chief Business Officer
Phone: +1 917-284-2911
uri@brainstorm-cell.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-third-quarter-2026-financial-results-and-provides-corporate-update-302940842.html

SOURCE BrainStorm Cell Therapeutics Inc.